Lexicon, Novo Nordisk start obesity drug study

Lexicon Pharmaceuticals and Novo Nordisk have announced the initiation of a Phase 1 study for LX9851, an oral drug candidate targeting obesity. LX9851 is described as a first-in-class, oral non-incretin therapeutic being developed for the treatment of obesity and related metabolic disorders. This collaboration marks a significant step in the development of new pharmacological interventions for a widespread health issue. The initiation of the Phase 1 study signifies the progression of this promising candidate into human clinical trials.